In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7620 consecutive clinical bacterial isolates
- 1 November 1986
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 5 (4), 345-349
- https://doi.org/10.1016/0732-8893(86)90041-6
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporinAntimicrobial Agents and Chemotherapy, 1985
- In vitro activities of Ro 17-2301 and aztreonam compared with those of other new beta-lactam antibiotics against clinical isolates of Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1985
- In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibioticAntimicrobial Agents and Chemotherapy, 1985
- The in-vitro activity of Ro 17-2301, a new monobactam, compared with other antimicrobial agentsJournal of Antimicrobial Chemotherapy, 1985
- Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic beta-lactam, in humansAntimicrobial Agents and Chemotherapy, 1984
- Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporinsAntimicrobial Agents and Chemotherapy, 1984